Snow Lake Resources 株価情報 (NASDAQ: LITM)

最新ニュース Snow Lake Resources (NASDAQ:LITM) 株価情報

Snow Lake Resources

Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.

Snow Lake Resources Ltd

Litman Gregory Funds Trust IMGP Berkshire Dividend Growth ETF

Litman Gregory Funds Trust Im Rba Responsible Global Allocation ETF

Litman Gregory Funds Trust Polen Capital China Growth ETF

Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF

Litman Gregory Funds Trust Polen Capital Global Growth ETF

Litman Gregory Funds Trust Polen Capital International Growth ETF

Litman Gregory Funds Trust iMGP DBi Hedge Strategy ETF

A total of <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">72 cryptocurrency-related exchange-traded funds</a> are currently awaiting approval by the U.S. Securities and Exchange Commission, according to Bloomberg ETF analyst Eric Balchunas.
What Happened: These pending <a href="https://x.com/EricBalchunas/status/1914336419314643103">applications</a> span a wide range of crypto assets, including mainstream tokens like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), as well as meme coins such as Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and themed funds like "2x Melania."
The ETFs cover various categories including spot products, leveraged and inverse ETFs, staking-based funds and derivative structures such as futures and options.
Products tied to Bitcoin and Ethereum remain the most common, but filings also include funds targeting Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>), Polkadot (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/dot/usd">DOT</a>), Aptos (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>), Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>), Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) and others.
From the shared filing dashboard, key asset managers with pending applications include Grayscale, Bitwise, ProShares, VanEck, 21Shares, CoinShares, Tuttle Capital and Canaray.
Tickers such as "BITW," "GBTC," and "SOLZ" show multiple pending deadlines in 2025.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44917155/xrp-leads-ethereum-bleeds-as-crypto-investment-products-see-6-million-in-inflows">XRP Leads, Ethereum Bleeds As Crypto Investment Products See $6 Million In Inflows</a>
What&#8217;s Next: Bitwise's Solana ETF has a final SEC decision deadline set for July 23, while Grayscale's Litecoin Trust must clear a second deadline by June 15.
ProShares has also filed for several double-leveraged or inverse Solana and XRP ETFs, with tentative decision dates listed through May and June 2025.
Many of the ETF proposals also fall under Rule 19b-4 of the Securities Exchange Act, requiring formal SEC rule changes for listing. 
Some filings are marked under the Investment Company Act of 1940 ('40 Act), which governs mutual funds and ETFs involving derivatives and leverage.
Notably, no final approvals are indicated for any of the crypto-themed ETFs listed beyond existing spot Bitcoin products.
Bloomberg analyst Eric Balchunas stated, "There are now 72 crypto-related ETFs sitting with the SEC awaiting approval to list or list options. Everything from XRP, Litecoin and Solana to Penguins, Doge and 2x Melania and everything in between. Gonna be a wild year."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44901448/5-catalysts-that-could-drive-bitcoin-higher-bernstein">5 Catalysts That Could Drive Bitcoin Higher: Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

$APT

$AVAX

$BTC

$DOGE

$DOT

$ETH

$HBAR

$LINK

$SOL

$XRP

XRP, Solana, Dogecoin Among 72 Crypto-Related ETFs Awaiting SEC Approval,

Cantor Fitzgerald analyst Carter Gould initiates coverage on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral rating and announces Price Target of $24.

Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Pfizer with Neutral Rating, Announces Price Target of $24

Cantor Fitzgerald analyst Carter Gould initiates coverage on Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Overweight rating.

PCVX

Cantor Fitzgerald Initiates Coverage On Vaxcyte with Overweight Rating

UBS analyst Rodrigo Alcantara downgrades Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) from Buy to Neutral.

Downgrades

ABEV

UBS Downgrades Ambev to Neutral

Cantor Fitzgerald analyst Carter Gould initiates coverage on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Neutral rating and announces Price Target of $85.

Cantor Fitzgerald Initiates Coverage On Merck & Co with Neutral Rating, Announces Price Target of $85

<ul>
<li>Written response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation &amp; Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma</li>
<li>Analysis to be featured at keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT</li>
</ul>
OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food &amp; Drug Administration ("FDA") granted the Company's meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation &amp; Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA granted a written response-only meeting and confirmed that its response would be received by mid-June 2025, in time for the Company to present the statistical analysis as part of the keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT.
OST-HER2 has received Rare Pediatric Disease Designation (RPDD) for osteosarcoma from the US FDA, and if it receives a conditional BLA via Accelerated Review prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fzevra-net-150m-priority-review-voucher-sale-tied-miplyffa-approval&amp;esheet=54241358&amp;newsitemid=20250422058584&amp;lan=en-US&amp;anchor=PRV+sale&amp;index=1&amp;md5=886faa5e273e3a04cb449996d51edd2d">PRV sale</a>, valued at $150 million, occurred in February 2025.
The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59%. 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30%. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million.
OST-HER2, an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2, is being featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. A trailer for the movie is available <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dz2YLhT3bb1Q&amp;esheet=54241358&amp;newsitemid=20250422058584&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=8fe71c66dba551b5cf18de8a0baa014f">here</a>. The movie will air live nationally on PBS and be available via streaming on PBS' website in early May 2025.

OSTX

OS Therapies Granted FDA Meeting Request To Gain Alignment On Surrogate Endpoint To Support Breakthrough Therapy Designation & Accelerated Approval Of OST-HER2 In Prevention Of Recurrence Of Fully Resected, Lung Metastatic Osteosarcoma

Cantor Fitzgerald analyst Carter Gould initiates coverage on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight rating and announces Price Target of $975.

Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces Price Target of $975

Citigroup analyst Tyler Radke initiates coverage on CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Neutral rating and announces Price Target of $43.

CRWV

Citigroup Initiates Coverage On CoreWeave with Neutral Rating, Announces Price Target of $43

WIIM

BCTX

BriaCell shares are trading higher after the company reported enrollment progress in its Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in advanced metastatic breast cancer.

Vice President JD Vance announced that the U.S. and India have&nbsp;set the terms for a trade negotiation, reiterating to double bilateral trade to&nbsp;a whopping $500 billion by the end of the decade.
What Happened: In a notable address at the India-U.S. Forum in Jaipur, India, on Tuesday, Vance articulated a bold vision for deepening ties between the United States and India. The potential deal marks a crucial step towards realizing the goal set by President Donald Trump and Indian Prime Minister Narendra Modi in February. The deal is expected to focus on job creation, resilient supply chains, and prosperity for workers in both nations.
&#8220;America and India have officially finalized the terms of reference for the trade negotiation,&#8221; says JD Vance.
Vance outlined three key areas of cooperation: defense, energy, and technology. The U.S.-India Compact will enhance the defense relationship through co-production of munitions and equipment, including the proposed American F-35 jets, to strengthen India&#8217;s air defenses.
Emphasizing energy security, Vance highlighted the potential benefits to India from expanded American oil and gas production and urged India to lower&nbsp;non-tariff barriers to American energy&nbsp;products.
On the technology front, Vance lauded&nbsp;the U.S.-India Trust Initiative as&nbsp;a foundation for future collaboration, suggesting a synergy between India&#8217;s startup ecosystem and America&#8217;s AI hardware prowess.
The Vice President also slammed the previous U.S. administrations for treating India only as a &#8216;source of low cost labor.&#8217; Speaking about Trump&#8217;s vision, Vance stated, &#8220;He wants America to grow, he wants India to grow.&#8221; 
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/44895420/jim-cramer-recommends-staying-away-from-amc-says-absolutely-no-to-webull" target="_blank" rel="noreferrer noopener">Jim Cramer Recommends Staying Away From AMC, Says &#8216;Absolutely No&#8217; To Webull</a>
Why It Matters: The framework of the agreement comes after&nbsp;<a href="https://www.benzinga.com/25/04/44894320/jd-vance-to-meet-prime-minister-modi-in-india-3-things-on-his-list">Vance&#8217;s visit to India</a>&nbsp;amid escalating global trade disputes. The visit, marked by discussions with Prime Minister Modi, aimed at easing trade tensions sparked by Trump&#8217;s tariff policies.
However, the proposed trade deal has not been without controversy. The All India Kisan Sabha (All India Farmers Union) expressed concerns that the agreement could&nbsp;threaten the livelihoods of <a href="https://www.benzinga.com/news/global/25/04/44893920/us-vice-president-vance-faces-backlash-from-all-india-farmers-union-who-claim-bilateral-trade-talks-will-undermine-indian-farmers-and-warn-india-is-not-for-sale">Indian farmers</a>.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44915713/charlie-munger-once-said-he-could-go-on-and-on-listing-why-he-wont-want-donald-trump-in-the-oval-office" target="_blank" rel="noreferrer noopener">Charlie Munger Once Predicted That Trump Could Be &#8216;Quite Decisive&#8217; But Still Didn&#8217;t Want Him To Be President: Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

JD Vance Finalizes Terms For Trade Deal With India's PM Modi, Says Trump Wants America And India 'To Grow'

Cantor Fitzgerald analyst Carter Gould assumes Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight rating and announces Price Target of $125.

GILD

Cantor Fitzgerald Assumes Gilead Sciences at Overweight, Announces Price Target of $125

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Mike Cikos initiated coverage on CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Buy rating and announced a price target of $55. CoreWeave shares closed at $35.42 on Monday. <a href="https://www.benzinga.com/quote/CRWV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst John Dunigan initiated coverage on Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Hold rating and announced a price target of $175. Avery Dennison shares closed at $169.03 on Monday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Kevin Cassidy initiated coverage on Blaize Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral rating and announced a price target of $3. Blaize Holdings shares closed at $2.67 on Monday. <a href="https://www.benzinga.com/quote/BZAI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Eric Beaumont initiated coverage on American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) with an Underweight rating and announced a price target of $138. American Water Works shares closed at $147.13 on Monday. <a href="https://www.benzinga.com/quote/AWK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Carter Gould initiated coverage on AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with an Overweight rating and announced a price target of $210. AbbVie shares closed at $170.16 on Monday.  <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="625" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-1024x625.png" alt="" class="wp-image-881626" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-1024x625.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

ABBV

BZAI

This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday

Cantor Fitzgerald analyst Carter Gould assumes Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral rating and announces Price Target of $55.

Cantor Fitzgerald Assumes Bristol-Myers Squibb at Neutral, Announces Price Target of $55

Guidance

Lockheed Martin Says '2025 outlook does not include the evolving impacts of tariffs or related recoveries, the recent Next Generation Air Dominance announcement, or Executive Orders issued by the Administration'

Citigroup analyst Gustavo Schroden upgrades StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) from Neutral to Buy and raises the price target from $9 to $15.

Upgrades

STNE

Citigroup Upgrades StoneCo to Buy, Raises Price Target to $15

Fifth issued patent in the U.S. for QTORIN&#x2122; rapamycin with anticipated patent life extending into 2038
QTORIN&#x2122; rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S.
WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No. 12,268,673 for claims related to the Company's lead product candidate QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin). The newly granted U.S. patent is part of Palvella's expanding intellectual property portfolio directed to novel therapies targeting microcystic lymphatic malformations (microcystic LMs) and other rare skin diseases.
The granted patent "Anhydrous Compositions of mTOR Inhibitors and Methods of Use" broadens protection for QTORIN&#x2122; rapamycin and the conditions related to its use in clinical indications, including microcystic LMs.

PVLA

Palvella Therapeutics: USPTO Issues Patent For Claims Related To Palvella's Product Candidate QTORIN 3.9% Rapamycin Anhydrous Gel

Biotech

General

BriaCell Says It Has Consented Over 100 And Has Enrolled Over 75 Patients In Phase 3 Study Of Bria-IMT Plus Immune Check Point Inhibitor Versus Physician's Choice In Advanced Metastatic Breast Cancer

Earnings

Earnings Beats

HOPE

Hope Bancorp Q1 EPS $0.19, Inline, Sales $116.50M Beat $114.97M Estimate

CREX

Creative Realities Has Been Selected By A Well-known, Upscale Quick Service Restaurant Chain, With Over 1,000 Locations Across More Than 25 U.S. States, To Lead The Transformation Of Its Indoor And Outdoor Menu Boards

United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 13.46 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $247.68 million which beat the analyst consensus estimate of $246.95 million by 0.30 percent. This is a 3.75 percent increase over sales of $238.74 million the same period last year.

United Community Banks Q1 Adj EPS $0.59 Beats $0.56 Estimate, Sales $247.68M Beat $246.95M Estimate

Press Releases

Snow Lake Exploration Program Underway at Engo Valley Uranium Project

Snow Lake Updates on the Joint Venture with Global Uranium and Enrichment Limited on the Pine Ridge Uranium Project

Snow Lake Phase 2 Drill Program Underway at Engo Valley

LITM

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

Comments

Snow Lake Resources

ニュース

最新ニュース Snow Lake Resources (NASDAQ:LITM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル